This site provides information on the EPIC study and details on case recruitment for veterinary professionals worldwide. Pimobendan is a prescription only medicine, licensed for the treatment of congestive heart failure due to mitral valve disease or dilated cardiomyopathy.

The EPIC Trial site is intended for veterinary professionals. By clicking 'Continue' you are affirming that you are a veterinary professional.

Evaluating Pimobendan in Cardiomegaly
Media & Journalists  •  Contact  •  Helpful Links  •  FAQs  •  Site Map

Groundbreaking news in canine cardiology - EPIC Study results are now available!

Results of the EPIC (Evaluation of Pimobendan in Cardiomegaly) Study have been published in the Journal of Veterinary Medicine. Click here to access the publication

EPIC: The largest veterinary cardiology study EVER
     •  36 trial centres, 360 dogs, 11 countries, over 5 years
     •  Results show that administration of pimobendan to dogs with mitral valve
        disease and echocardiographic and radiographic evidence of cardiomegaly
        results in prolongation of preclinical period by approximately
        15 months
, which represents substantial clinical benefit

The EPIC Trial website will be updated with more information soon!

Further details on the study can be found at the Royal Veterinary College website.

Investigator Sign in

Investigators, please sign in here.

Study Design

Learn more about EPIC and canine heart disease

Trial Locations

36 investigators, 11 countries, four continents



An investigator's point of view



The latest study updates


The answers to most of your questions

About the Trial

Learn more about the history of the EPIC Trial, how it came to be and what the study aims to uncover.

EPIC Trial Progress

Click here to see how many dogs are currently enrolled and to track the growth of the EPIC Trial.

What is MMVD and CHF?

Understanding canine heart disease.